Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Empreendimentos Pague Menos S.A. (PGMN3.SA)
Fortaleza, CE, BR
Empreendimentos Pague Menos S.A. operates a prominent pharmacy chain across Brazil, offering a comprehensive array of health and wellness products. Their extensive inventory includes a wide variety of medications spanning numerous therapeutic categories such as pain relief, allergy treatment, digestive health, diabetes management, and vitamins. Beyond pharmaceuticals, the company provides a vast selection of personal care and beauty products, dermo-cosmetics, and specialized items for mothers and babies. They also stock general merchandise, including toys, clothing, food, beverages, and various household essentials. Established in 1981 and headquartered in Fortaleza, Brazil, Pague Menos manages a substantial retail network of 1,105 stores throughout the country.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.59% | -5.73% | -15.70% | -29.43% | +8.10% | -20.96% | +50.61% | +92.97% | -42.02% | -40.05% | -40.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+17.9% ★ Q1'26: +13.0% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+147.1% ★ Q1'26: +840.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+1.2% Q1'26: +0.9% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+5.7% Q1'26: +5.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+12.9% ★ Q1'26: +11.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+3.6% Q1'26: +11.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×2.68× Q1'26: 2.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 2 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.86B
est: 6.72B (+2.1%)
|
7.53B
est: 7.43B (+1.4%)
|
9.19B
est: 9.21B (-0.2%)
|
11.20B
est: 11.77B (-4.8%)
|
12.64B
est: 12.96B (-2.5%)
|
14.91B
est: 15.13B (-1.5%)
|
17.10B
16.74B – 18.05B
+13.1% YoY
|
18.92B
17.61B – 20.63B
+10.6% YoY
|
20.43B
19.76B – 21.10B
+8.0% YoY
|
23.31B
22.23B – 25.04B
+14.1% YoY
|
28.63B
27.30B – 30.75B
+22.8% YoY
|
| EBITDA |
777.35M
est: 622.17M (+24.9%)
|
732.20M
est: 687.66M (+6.5%)
|
965.84M
est: 852.37M (+13.3%)
|
797.92M
est: 1.04B (-23.3%)
|
961.06M
est: 1.15B (-16.1%)
|
1.38B
est: 1.34B (+2.9%)
|
1.51B
1.48B – 1.60B
+13.1% YoY
|
1.67B
1.56B – 1.82B
+10.6% YoY
|
1.81B
1.75B – 1.86B
+8.0% YoY
|
2.06B
1.96B – 2.21B
+14.1% YoY
|
2.53B
2.41B – 2.72B
+22.8% YoY
|
| EBIT |
526.76M
est: 348.30M (+51.2%)
|
453.55M
est: 384.96M (+17.8%)
|
578.22M
est: 477.17M (+21.2%)
|
270.66M
est: 563.25M (-51.9%)
|
439.39M
est: 620.50M (-29.2%)
|
849.41M
est: 724.16M (+17.3%)
|
818.74M
801.22M – 863.90M
+13.1% YoY
|
905.46M
843.14M – 987.38M
+10.6% YoY
|
977.96M
946.09M – 1.01B
+8.0% YoY
|
1.12B
1.06B – 1.20B
+14.1% YoY
|
1.37B
1.31B – 1.47B
+22.8% YoY
|
| Net Income |
96.03M
est: 101.61M (-5.5%)
|
164.46M
est: 215.08M (-23.5%)
|
263.66M
est: 181.12M (+45.6%)
|
219.0K
est: 113.47M (-99.8%)
|
103.10M
est: 111.51M (-7.5%)
|
260.28M
est: 239.08M (+8.9%)
|
311.81M
300.47M – 323.15M
+30.4% YoY
|
403.17M
345.57M – 460.76M
+29.3% YoY
|
456.82M
369.31M – 544.33M
+13.3% YoY
|
440.23M
413.55M – 482.55M
-3.6% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
1.80B
est: 1.84B (-2.2%)
|
2.05B
est: 2.04B (+0.5%)
|
2.58B
est: 2.53B (+2.1%)
|
3.17B
est: 3.23B (-1.9%)
|
3.46B
est: 3.56B (-2.7%)
|
3.91B
est: 4.15B (-5.7%)
|
4.69B
4.59B – 4.95B
+13.1% YoY
|
5.19B
4.83B – 5.66B
+10.6% YoY
|
5.61B
5.42B – 5.79B
+8.0% YoY
|
6.40B
6.10B – 6.87B
+14.1% YoY
|
7.86B
7.49B – 8.44B
+22.8% YoY
|
| EPS |
0.25
est: 0.17 (+47.2%)
|
0.36
est: 0.36 (+0.1%)
|
0.59
est: 0.31 (+91.0%)
|
0.01
est: 0.18 (-97.1%)
|
0.18
est: 0.18 (+1.9%)
|
0.42
est: 0.39 (+8.9%)
|
0.50
0.48 – 0.52
+30.4% YoY
|
0.65
0.56 – 0.74
+28.7% YoY
|
0.74
0.60 – 0.88
+13.8% YoY
|
0.71
0.67 – 0.78
-3.6% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck Brazil Small-Cap ETF BRF | 0.59% | 135.5K | 0.60% |
| 2 | Matthews Emerging Markets Discovery Active ETF MEMS MEMS | 0.36% | 80.4K | 0.99% |
| 3 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 42.7K | 0.56% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 630.8K | 0.39% |
| 5 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 8.0K | 0.42% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 122.0K | 0.46% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 33.5K | 0.44% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 15.0K | 0.33% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 318.7K | 0.29% |
| 10 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 7.5K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carlos do Prado Fernandes | Vice President of Operations | — | — |
| Jonas Marques | Chief Executive Officer | — | male |
| Luiz Renato Novais | Chief Financial & Investor Relations Officer | — | male |
| Renato Camargo Nascimento Jr. | Vice President of Marketing & Customer Relations | — | — |
| Rosilane Oliveira Purceti Balabram | Vice President of People, Culture & Sustainability | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PGMN3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
